Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.

chart

Eli Lilly & Co.’s third quarter sales gains were driven largely by new products that are facing high-profile competition and reimbursement pressures, but the company says it is on track to meet revenue goals through 2020 even if the potential Alzheimer’s blockbuster therapy solanezumab fails in the Phase III EXPEDITION-3 clinical trial expected to report later this year.

That’s good news for Lilly’s investors, considering the long list of failures in Alzheimer’s disease, including two previously failed Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.